MS progression and immune cells after bone marrow transplant and other therapies
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have relapsing-remitting MS (RRMS) as diagnosed by current standards
- You have had at least 2 relapses in the past year, or 1 relapse plus new MRI lesions in the past year
- You are being considered for one of these treatments: bone marrow transplant, alemtuzumab, ocrelizumab, or ofatumumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat primary progressive multiple sclerosis (PPMS) using a stem cell transplant from a healthy donor. The goal is to see if this approach can stop or slow the disease and improve quality of life.
This trial uses your own blood stem cells to reboot your immune system, which may help stop multiple sclerosis attacks and slow disability. It is for people with active MS that has not responded well to other treatments.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
This trial tests a new treatment using a patient's own immune cells, modified with vitamin D3, to try to calm the immune system and slow the progression of multiple sclerosis (MS) without causing major side effects. It is for people with progressive MS who have not had recent relapses.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.